CIK 0001677077 · <br>Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811822909
- Phone
- 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 4 Other acquisition 10% owner acquired 73,500 shares (other)
- 8-K Event Regulation FD disclosure
- 4 Open-market buy Chief Executive Officer bought 8,500 shares at $1.23 ($10,414)
- 4 Open-market buy Chief Financial Officer bought 10,000 shares at $1.11 ($11,092)
- 10-Q Report Quarterly Report
- 4 Open-market buy 10% owner bought 9,100 shares at $0.94 ($8,561)
- 4 Open-market buy 10% owner bought 4,900 shares at $0.96 ($4,704)
- 4 Open-market buy 10% owner bought 36,000 shares at $0.97 ($34,895)
- 4 Open-market buy 10% owner bought 15,000 shares at $1.08 ($16,214)
- 4 Open-market buy 10% owner bought 14,000 shares at $1.06 ($14,833)
- 8-K Event Regulation FD disclosure
- 4 Open-market buy 10% owner bought 1,000 shares at $1.04 ($1,040)
- 8-K Event Executive or director change
- 4 Open-market buy 10% owner bought 2,000 shares at $0.95 ($1,896)
- 4 Open-market buy 10% owner bought 5,700 shares at $0.87 ($4,959)
- 4 Open-market buy 10% owner bought 2,300 shares at $0.91 ($2,082)
- 10-K Report Annual Report
- 4 Open-market buy 10% owner bought 10,000 shares at $0.98 ($9,773)
- 8-K Event Delisting notice
- 4 Open-market buy 10% owner bought 10,000 shares at $0.88 ($8,830)
Page 11 of 20 · 398 filings